Merrimack Pharmaceutical Inc – (MACK, +1, January 4th)
Eric Andersen (Non-Executive since 2019) bought $2.8 million of stock on the 30th of December at $10.67, increasing his stake by 20%. The purchases were indirect and on behalf of Western Standard, they now own 11.4% of the outstanding shares. They made a series of purchases into rising prices, buying initially at $2.88 in April 2020 and most recently at $6.42 in April 2021.
It’s notable to see them now making their largest purchase after very strong share price performance triggered by positive results in a pancreatic cancer clinical drug trial. We are ranking the stock +1. Note that on Andersen/Western Standard’s Form 4 filing, they refer to an agreement with Newtyn Partners (Noah Levy, Director) under which they agree to vote their shares as a “group” which would add up to a combined beneficial ownership of now 24.6% of the company.
We are ranking the stock +1.
If you want to have Stock of the Week with insider buying stocks information and analysis in your email, don’t forget to subscribe!
Follow us on LinkedIn and Twitter
Check our Signals Performance and if you want to know more about this Signals Service, please, email us at firstname.lastname@example.org or fill in the Contact Us form here.